ABUS is expected to report earnings to fall 103.45% to -2 cents per share on July 30
Q2'26
Est.
$-0.03
Q1'26
Beat
by $0.91
Q4'25
Missed
by $0.14
Q3'25
Missed
by $0.01
Q2'25
Beat
by $0.05
The last earnings report on May 13 showed earnings per share of 87 cents, beating the estimate of -3 cents. With 1.89M shares outstanding, the current market capitalization sits at 890.90M.
A.I. Advisor
published General Information
General Information
a developer of drugs to improve the treatment of cancer
A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with XNCR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then XNCR could also see price increases.
Aroon Indicator for ABUS shows an upward move is likely
ABUS's Aroon Indicator triggered a bullish signal on June 04, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 235 similar instances where the Aroon Indicator showed a similar pattern. In of the 235 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 16, 2026. You may want to consider a long position or call options on ABUS as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ABUS just turned positive on June 17, 2026. Looking at past instances where ABUS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
ABUS moved above its 50-day moving average on June 16, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for ABUS crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for ABUS moved below the 200-day moving average on June 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ABUS broke above its upper Bollinger Band on June 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.425) is normal, around the industry mean (20.966). P/E Ratio (5.434) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ABUS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (4.539) is also within normal values, averaging (367.026).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
